WO2025021198 - PolQ DEGRADERS, COMPOSITIONS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/021198
Publication Date
30.01.2025
International Application No.
PCT/CN2024/107825
International Filing Date
26.07.2024
Title **
[English]
PolQ DEGRADERS, COMPOSITIONS AND USES THEREOF
[French]
AGENTS DE DÉGRADATION DE POLQ, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
Applicants **
DANATLAS PHARMACEUTICALS CO., LTD.
Inventors
ZHOU, Wenlai
ZHUO, Jincong
Priority Data
PCT/CN2023/109588
27.07.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3670 | |
| EPO | Filing, Examination, Granting | 39980 | |
| Japan | Filing, Examination, Granting | 3418 | |
| South Korea | Filing, Examination, Granting | 4847 | |
| USA | Filing, Examination, Granting | 18990 |
Total:
70,905
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are bifunctional compounds useful as modulators of targeted ubiquitination, especially with respect to PolQ as shown in Formula (I), pharmaceutical compositions comprising them, a process for their preparation, and their use as therapeutic agents.[French]
L'invention concerne des composés bifonctionnels utiles en tant que modulateurs de l'ubiquitination ciblée, en particulier par rapport à PolQ tels que représentés dans la formule (I), des compositions pharmaceutiques les comprenant, un procédé pour leur préparation, et leur utilisation en tant qu'agents thérapeutiques.